CA
Caris Life Sciences, Inc.
CAI · NASDAQ
$28.50 +10.47% (+$2.70)
1M +31.76%
Market Cap $8.06B
P/E Ratio 76.63x
Div. Yield -
ROE 18.77%
Piotroski F-Score Moderate
5/9Valuation
0 /100
Expensive EV/EBITDA 45.27x
P/S 8.14x
P/B 13.61x
Growth
100 /100
Growing Rev. growth 46.46%
FCF growth N/A
Book val. growth N/A
Profitability
79 /100
Strong Net margin 10.62%
Op. margin 15.49%
FCF margin 14.80%
Quality
79 /100
Excellent ROE 18.77%
ROA 8.55%
Asset turnover 0.80x
Debt
78 /100
Low Current ratio 5.53x
Int. coverage 3.24x
Net debt/EBITDA -1.38x
Stability
41 /100
Moderate Rev. volatility 41.46%
EPS volatility 39.17%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CAI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Dean Halbert
Employees
1,846
Headquarters
Irving
Upcoming events
04 NOV
Earnings
Upcoming earnings report